FAQs

1. How high are the dividend payments?

For financial year 2012 a dividend in the amount of EUR 0.50 was approved and distributed on June 06, 2013.

2. How high were earnings per share (EPS) in recent years?

*Adjusted for one-time special effects

3. When is the next Annual General Meeting?

The next Annual General Meeting will take place on June 4, 2014 in Frankfurt am Main, Germany, at the Congress Center of the Frankfurt Fair.

4. How does STADA comply with the Corporate Governance Code?

Click here for the Declaration of Compliance.

5. Which stock market indices include the STADA share?

The STADA share is included on the following indices:

• MDAX of Deutsche Börse AG since July 2001
• Dow Jones EuroSTOXXSM 600, which includes 200 European Large, Mid and Small-caps, since December 2002.
• MSCI Small Cap Europe since May 30, 2003.

Important pharmaceutical indices that include the STADA share include, among others:

• Bloomberg Pharmaceutical Index (BEPHARM)
• Dow Jones EuropeanStoxx Healthcare Price Index (SXDE)
• DJ STOXX Healthcare Price Index (SXDP)
• Prime Pharma & Healthcare Performance Index (CXPP)

6. When was STADA founded and when was it floated?

STADA was founded as a pharmacists' association in 1895 in Dresden with the name "Standardarzneimittel für deutsche Apotheker". It became a joint stock corporation in 1970 with the initial public offering in 1997. Further milestones you can find here.

7. How can STADA's shareholder structure be broken down?

On December 31, 2012, a total of approx. 42,000 shareholders held share capital of STADA Arzneimittel AG. Based on results of regularly occurring analyses of the Company’s shareholder structure, STADA assumes that at least approx. 58% of STADA’s shares are held by institutional investors and that approx. 12% of STADA’s capital is held by pharmacists and doctors.

8. What is the outlook for 2013?

• Further growth in Group sales
• Opportunity for renewed growth in adjusted EBITDA* in the high single-digit percentage area

*Adjusted for one-time special effects.

9. What is the outlook for 2014*?

• Group sales: approx. EUR 2.15 billion
• Adjusted EBITDA: approx. EUR 430 million
• Adjusted net income: approx. EUR 215 million

*See the Company’s ad hoc releases of June 7, 2010, March 1, 2012 and February 28, 2013.

10. Is it possible to receive regular updates about STADA?

This website publishes all the important news about STADA.

Please click here to subscribe to the STADA Newsletter. Enter your email address to automatically receive the latest company news about STADA Arzneimittel AG via email on a regular basis.